Stelvio Oncology has developed an epigenetic signature based platform for identifying compounds that drive differentiation of cancer stem cells into benign cell types.
Stelvio Oncology
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.stelvio-oncology.com
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address479 Jessie Street, CA 94103San FranciscoUnited States
479 Jessie Street, CA 94103
San Francisco
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/stelvio-oncology” connections=”true” suffix=””]